Enhanced Osteogenic and Vasculogenic Differentiation Potential of Human Adipose Stem Cells on Biphasic Calcium Phosphate Scaffolds in Fibrin Gels.
Enhanced Osteogenic and Vasculogenic Differentiation Potential of Human Adipose Stem Cells on Biphasic Calcium Phosphate Scaffolds in Fibrin Gels.
复制标题
人脂肪干细胞在纤维蛋白凝胶中增强的成骨和血管生成分化潜力。
DOI：
10.1155/2016/1934270
复制
发表时间：
2016
影响因子：
4.3
通讯作者：
Klein-Nulend J
中科院分区：
文献类型：
--
作者：
van Esterik FA;Zandieh-Doulabi B;Kleverlaan CJ;Klein-Nulend J
在骨组织工程中，人工合成的羟基磷灰石/β-磷酸三钙(HA/β-TcP)比例为60/40(BCP60/40)的双相磷酸钙已成功应用于骨组织工程，但高比例的HA可能会阻碍支架的有效重建。具有较低HA/β-TCP值(BCP20/80)的BCP是否更可取仍不清楚。在发生成骨之前，需要血管发育。我们的目的是测试在BCP60/40或BCP20/80上种植的人脂肪干细胞(ASCs)在纤维蛋白凝胶中的成骨和/或血管形成分化潜力以及降解情况，以触发新生血管以促进骨再生。在30 分钟内，BCP60/40和BCP20/80的ASC附着相似(93%)。培养11d后，与BCP60/40复合材料相比，BCP20/80复合材料的碱性磷酸酶活性和DMP1基因表达增强，而RUNX2和骨连接蛋白的表达无明显变化。基于BCP20/80的复合材料还显示血管生成标志CD31和VEGF189的表达增强，而VEGF165和内皮素-1的表达没有增强。胶原-1和胶原-3在两种复合材料中的表达相似。BCP20/80/BCP20/80复合材料的纤维蛋白降解在第7天开始加速。结论：与基于BCP60/40的复合材料相比，基于BCP20/80的复合材料在体外显示出更强的成骨和血管分化潜能，提示基于BCP20/80的复合材料可能比基于BCP60/40的复合材料更有希望用于体内的骨强化。
For bone tissue engineering synthetic biphasic calcium phosphate (BCP) with a hydroxyapatite/β-tricalcium phosphate (HA/β-TCP) ratio of 60/40 (BCP60/40) is successfully clinically applied, but the high percentage of HA may hamper efficient scaffold remodelling. Whether BCP with a lower HA/β-TCP ratio (BCP20/80) is more desirable is still unclear. Vascular development is needed before osteogenesis can occur. We aimed to test the osteogenic and/or vasculogenic differentiation potential as well as degradation of composites consisting of human adipose stem cells (ASCs) seeded on BCP60/40 or BCP20/80 incorporated in fibrin gels that trigger neovascularization for bone regeneration. ASC attachment to BCP60/40 and BCP20/80 within 30 min was similar (>93%). After 11 days of culture BCP20/80-based composites showed increased alkaline phosphatase activity and DMP1 gene expression, but not RUNX2 and osteonectin expression, compared to BCP60/40-based composites. BCP20/80-based composites also showed enhanced expression of the vasculogenic markers CD31 and VEGF189, but not VEGF165 and endothelin-1. Collagen-1 and collagen-3 expression was similar in both composites. Fibrin degradation was increased in BCP20/80-based composites at day 7. In conclusion, BCP20/80-based composites showed enhanced osteogenic and vasculogenic differentiation potential compared to BCP60/40-based composites in vitro, suggesting that BCP20/80-based composites might be more promising for in vivo bone augmentation than BCP60/40-based composites.